Polygenic risk score (PRS) as prostate cancer screening: ready for primetime?

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Annals of Translational Medicine

• Publication date

  2025-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.21037/atm-25-84PMID 40949682PMCID 12432619
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer statistics, 2025

  2025cited by this paper
• Assessment of a Polygenic Risk Score in Screening for Prostate Cancer

  2025cited by this paper
• Results from 22 years of Followup in the Göteborg Randomized Population-Based Prostate Cancer Screening Trial

  2022cited by this paper
• Polygenic risk score for genetic evaluation of prostate cancer risk in Asian populations: A narrative review

  2021cited by this paper
• The BARCODE1 Pilot: a feasibility study of using germline single nucleotide polymorphisms to target prostate cancer screening

  2021cited by this paper
• Polygenic hazard score is associated with prostate cancer in multi-ethnic populations

  2019cited by this paper
• Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations

  2018cited by this paper
• Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial

  2018cited by this paper
• Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci

  2018cited by this paper
• A Review of Prostate Cancer Genome-Wide Association Studies (GWAS)

  2018cited by this paper
• Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement

  2018cited by this paper
• Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials

  2017cited by this paper
• Extended mortality results for prostate cancer screening in the PLCO trial with median follow‐up of 15 years

  2017cited by this paper
• Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis

  2014cited by this paper
• Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

  2014cited by this paper
• Mortality results from a randomized prostate-cancer screening trial.

  2009cited by this paper
• Screening and prostate-cancer mortality in a randomized European study.

  2009cited by this paper

• No citing papers are available for this paper.